Semaglutide B 3.0 mg/ml PDS290

DRUG3 trials

Sponsors

Stichting Rijnstate Ziekenhuis, Stichting Zuyderland Medisch Centrum, Novo Nordisk A/S

Conditions

Atrial fibrillationNon-alcoholic steatohepatitis (NASH)Obesityobesity

Phase 2

Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial.

CompletedCTIS2023-506961-74-00

Novo Nordisk A/SNon-alcoholic steatohepatitis (NASH)

Start: 2021-08-31End: 2025-03-07Target: 165Updated: 2025-01-22

Phase 4

DUTCH Weight Control in Atrial Fibrillation Study

RecruitingCTIS2022-501392-81-00

Stichting Rijnstate ZiekenhuisAtrial fibrillation, Obesity

Start: 2024-07-25Target: 280Updated: 2025-05-07

Semaglutide 2.4mg for low responders after bariatric surgery

RecruitingCTIS2022-502164-20-01

Stichting Zuyderland Medisch Centrumobesity

Start: 2025-03-11Target: 152Updated: 2025-03-06